SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community emphasizes a steadfast commitment to "Bongterm" growth and positive culture, contrasting it with short-term hype. Discussions highlight the token's role within the evolving global cannabis movement and the anticipation of policy shifts impacting the sector. Members proudly position Weedcoin on Solana as a symbol of decentralized health and cultural sovereignty.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma (formerly Cybin Inc.) is trending following its recent rebrand and NASDAQ listing under the symbolic ticker $HELP, signaling a strategic shift towards late-stage clinical development in mental health. While some investors see this as a pivotal move to enhance visibility and believe the company is undervalued compared to its psychedelic sector peers, others express skepticism, viewing the rebranding as superficial given past stock performance and concerns about dilution. The community is actively debating the implications of this transition and eagerly awaiting upcoming clinical data for its HLP003 and HLP004 programs.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is currently trending following a significant increase in new addresses on its Shibarium network, sparking renewed optimism among many holders. While a vocal segment of the community remains "long strong confident" and anticipates potential price appreciation, others express skepticism, labeling it a speculative "scam" or "pump and dump" coin. This polarized sentiment highlights the ongoing debate surrounding its future as a prominent meme cryptocurrency.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A

Fortress Biotech's preferred shares ($FBIOP) are trending as the community eagerly anticipates the sale of a Priority Review Voucher (PRV) awarded to its subsidiary, Cyprium Therapeutics, following a recent drug approval. This significant cash infusion, alongside strong sales for Journey Medical's Emrosi and the expected Unloxcyt launch, is driving discussions about potential dividend reinstatement for preferred shareholders and the stock's perceived undervaluation.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is trending due to significant community discussion surrounding its recent appearance on decentralized exchanges and its potential for rapid gains. However, this optimism is met with strong skepticism and warnings from others who label it a likely meme coin or 'rug pull,' contributing to widespread confusion about its legitimacy and the correct way to acquire it.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics (UNCY) is trending as a recent 13G filing confirmed Millennium Management's significant ownership stake, signaling growing institutional interest. This institutional activity coincides with high community anticipation for the FDA's acceptance of the company's New Drug Application resubmission for Oxylanthanum Carbonate (OLC). Investors are optimistic about OLC's potential approval and the assignment of a PDUFA date, as the prior Complete Response Letter was related to manufacturing compliance, not the drug's efficacy.

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Foghorn Therapeutics Inc

Foghorn Therapeutics is trending amid heightened optimism surrounding its partnership with Eli Lilly, which has selected the FHD-909 program for clinical development, bolstered by recent positive preclinical data from AACR. The community largely views this as strong validation for their pioneering chromatin biology platform, anticipating significant future growth and potential acquisition interest, despite some acknowledging past program challenges.

Royal Gold, Inc. engages in the business of acquiring and managing precious metal streams, royalties, and similar interests. It operates under the Acquisition and Management of Stream Interests, and Acquisition and Management of Royalty Interests segments. The Acquisition and Management of Stream Interests segment focuses on metal streams, which are purchase agreements that provide, in exchange for an upfront deposit payment, the right to purchase all or a portion of one or more metals produced, at a price determined for the life of the transaction. The Acquisition and Management of Royalty Interests segment is involved in non-operating interests in mining projects that provide the right to revenue or metals produced from the project. The company was founded by Stanley Dempsey in 1981 and is headquartered in Denver, CO.

Royal Gold, Inc.

Royal Gold is gaining significant attention due to sustained strong precious metal prices and recent substantial analyst upgrades that reflect confidence in its future outlook. The company's strategic acquisitions and ongoing royalty agreements are enhancing its diversified portfolio, with the community actively discussing these moves as key long-term growth catalysts. Many investors maintain a bullish perspective, underscoring the strength of its royalty model and its role as a defensive metals play in the current market environment.

Toyota Motor Corp. engages in the manufacture and sale of motor vehicles and parts. It operates through the following segments: Automotive, Financial Services, and All Other. The Automotive segment designs, manufactures, assembles and sells passenger cars, minivans, trucks, and related vehicle parts and accessories. It is also involved in the development of intelligent transport systems. The Financial Services segment offers purchase or lease financing to Toyota vehicle dealers and customers. It also provides retail leasing through lease contracts purchased by dealers. The All Others segment deals with the design, manufacture, and sale of housing, telecommunications and other businesses. The company was founded by Kiichiro Toyoda on August 28, 1937 and is headquartered in Toyota, Japan.

Toyota Motor Corporation - ADR

Toyota Motor Corp.

Toyota is trending as investors monitor evolving US-Japan tariff discussions, which significantly influence its import costs and production strategies. This comes amid a notable corporate development concerning its potential buyout of Toyota Industries, met with activist investor scrutiny. The community is also keenly observing Toyota's strategic advancements in autonomous driving through a recent Waymo partnership, while evaluating its strong hybrid sales growth against broader industry shifts and EV market challenges.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain ($VET) is trending amidst widespread investor frustration over its consistent underperformance and declining market cap ranking, despite recent integrations with platforms like Crypto.com for institutional custody and ongoing Hayabusa network upgrades. The community remains sharply divided, with many long-term holders expressing disillusionment over the project's inability to translate its "on paper" partnerships and sustainability initiatives, such as VeBetterDAO, into meaningful price action compared to other altcoins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
